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Identity 








Location of the LYL1 gene, identified by Non-random 
chromosomal translocation t(7;19)(q35;p13) associated 
with T-cell acute lymphoblastic leukemia (T-ALL), 
was mapped to the short arm of chromosome 19 
(19p13) by in situ hybridization. 
Transcription 
Expression levels of LYL1 are comparatively higher in 
normal bone marrow, spleen, lung, thymus and spinal 
cord tissues. Ectopic transcription is observed in T-
lymphoblastic and myeloblastic leukemic cells. 
Protein 
Description 
LYL1 encodes a basic helix-loop-helix (bHLH) 
protein, with 267 amino acids and molecular weight of 
28628 Da. 
Localisation 
Subcellular location is potentially intracellular 
(nucleus). However, ectopic protein staining was 
observed in cytoplasm of myeloid leukemia cells with 
immunohistochemistry. 
Function 
Recent studies show that LYL1 is required for fetal and 
adult hematopoietic stem cell function and B-cell 
differentiation. Overexpression of LYL1 is implicated 
in the pathogenesis of T-ALL as well as myeloid 
malignancies (see below, disease implications). The 
LYL1 protein is a transcription factor (TF), structurally 
and functionally similar to another bHLH protein 
TAL1/SCL which is also implicated in T-ALL. 
Expression of both LYL1 and TAL1/SCL are regulated 
by the Ets and GATA factors; However, ectopic 
expression of SCL but not Lyl1 can rescue 
haematopoietic differentiation in SCL(-/-) ES-cells, 
providing a molecular explanation for the vastly 
different phenotypes of SCL(-/-) and Lyl1(-/-) mouse 
embryos. 
Efficient DNA binding of LYL1 requires dimerization 
with proteins. Specific in vivo association was 
observed between the bHLH and LIM proteins (LMO1 
and LMO2). LYL1 readily forms heterodimeric 
complexes with E2A and may function as a dominant-
negative preventing the activation of E2A responsive 
genes. LYL1 interacts also with p105 the precursor of 
NF-KappaB1 p50. 
Homology 
The bHLH region of LYL1 and TAL1/SCL proteins 
show 82% amino acid identity, suggesting that these 
two proteins share at least some target genes and 
biologic functions. However, LYL-1 and TAL1diverge 
largely outside the bHLH region and display a distinct 
expression pattern in hematopoietic cells. Mouse Lyl-1 












Atlas Genet Cytogenet Oncol Haematol. 2007;11(2)  100 
Implicated in 
t(7;19)(q35;p13) → TCRB /LYL1 in T-cell 
acute lymphoblastic leukemia, other T-
ALL, acute myeloblastic leukemia (AML) 
or myelodysplastic syndrome (MDS) 
Disease 
The LYL1 gene was originally identified at the 
chromosomal translocation t(7;19)(q35;p13) associated 
with T-ALL. However, over-expression of LYL1 has 
been reported in T-ALL cases without apparent 
chromosome aberration. Recent studies on leukemia 
cell lines and patient samples suggested its involvement 
in myeloid malignancies. Using real-time quantitative 
RT-PCR assay, the authors found that the expression of 
LYL1 was at a significantly higher level than normal 
bone marrow cells in the majority of cases of acute 
myeloblastic leukemia (AML) or myelodysplastic 
syndrome when compared to normal bone marrow. 
This study also showed that LYL1 was highly 
expressed in most AML cell lines and in CD34(+) 
AML cells. 
Prognosis 
Expression of LYL1 is associated with unfavorable 
prognosis in T-ALL cases. LYL1(+) cases have a gene 
expression signature corresponding to that of the most 
immature normal T-cell precursors (CD4/CD8 double-
negative cells), which express CD34 but not CD4, 
CD8, or CD3. Less favorable outcomes were observed 
in subgroups defined by gene expression profiles 
characteristic of TAL1(+) or LYL1(+) samples, which 
resemble late cortical and early pro-T thymocytes, 
respectively. 
Cytogenetics 
The LYL1 gene was originally identified at the 
breakpoint of the translocation t(7;19)(q35;p13) in 
cases of T-ALL. It is the LYL1 gene but not protein 
that is structurally altered following t(7;19), resulting in 
its head-to-head juxtaposition with the T-cell antigen 
receptor beta gene (TCR-beta). The translocation 
resulted in truncation of the LYL1 gene and production 
of abnormal-sized RNAs, bringing LYL1 gene under 
the regulatory control of TCR-beta, and thus resulting 
in its ectopic expression. In addition to the 
t(7;19)(q35;p13), other translocations are 
t(1;19)(p34;p13), t(1;19)(p32;p13), t(9;19)(q34;p13), 
t(9;19)(q32;p13), t(10;19)(q24;p13), t(11;19)(p13;p13), 
t(15;19)(q22;p13) etc; it is not known if all of the 
translocations lead to enhanced expression of LYL1. 
Hybrid/Mutated Gene 
The TCR-beta locus at 7q35 spans 685 kb (64-67 
variable genes TRBV, 2 clusters of diversity, joining 
and constant segments). 
 
Oncogenesis 
As discussed above, the LYL1 gene was first identified 
at t(7;19)(q35;p13) associated T-ALL. However, over-
expression of LYL1 has been reported in T-ALL cases 
without apparent chromosome aberration. LYL1, TAL1 
and TAL2 constitute a discrete subgroup of helix-loop-
helix proteins, each of which can potentially contribute 
to the development of T-ALL. Specific in vivo 
association between the bHLH and LIM proteins is 
implicated in human T cell leukemia. LYL1 can readily 
form heterodimers with E2A and NF-KappaB1 p105 
protein. It is possible that LYL1 may function as a 
dominant-negative preventing the activation of the 
tumor suppressors like E2A. Ectopic expression of 
LYL1 may also be involved in myeloid leukemia. 
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